About ANI Pharmaceuticals, Inc. - Common Stock (ANIP)
ANI Pharma Inc is a specialty pharmaceutical company focused on developing and commercializing a range of high-quality generic and branded prescription products, primarily in the fields of pain management, endocrinology, and complex formulations. The company aims to address the unique needs of patients by leveraging its expertise in drug formulation and development, while also striving to enhance patient access to its medications. ANI Pharma places a strong emphasis on innovation and quality, utilizing advanced technology to create differentiated products that target specific therapeutic areas. Read More
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP)
jumped 18.4% in the morning session after the company reported second-quarter earnings and revenue that surpassed analyst estimates and raised its full-year financial guidance. The specialty pharmaceutical company announced quarterly net revenues of $211.4 million, a 53.1% year-over-year increase that beat analyst estimates of $191.5 million. Adjusted earnings per share came in at $1.80, also significantly higher than the consensus forecast of $1.42. Bolstering investor confidence, ANI Pharmaceuticals increased its 2025 forecast, now expecting full-year revenues between $818 million and $843 million and adjusted earnings per share from $6.98 to $7.35, both well above prior guidance.
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q2 CY2025, with sales up 53.1% year on year to $211.4 million. The company’s full-year revenue guidance of $830.5 million at the midpoint came in 4.9% above analysts’ estimates. Its non-GAAP profit of $1.80 per share was 26.8% above analysts’ consensus estimates.
ANI Pharmaceuticals reports record Q2 2025 earnings, beating estimates with $211.4M revenue and $1.80 EPS. Shares surge 6.5% as company raises full-year guidance.
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a jury in the Superior Court of the State of Delaware (the “Court”) unanimously found in favor of CG Oncology on all claims in a March 2024 lawsuit brought by ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”). The jury unanimously rejected all of ANI Pharmaceuticals’ claims for unjust enrichment damages after Judge Sheldon K. Rennie, on July 16, 2025, had ruled in favor of CG Oncology that, as a matter of law, ANI Pharmaceuticals was not entitled to any royalties on future sales of cretostimogene grenadenorepvec. At present CG Oncology has not been advised as to whether ANI Pharmaceuticals will appeal any aspect of the decisions. As a result of today’s decision CG Oncology will not owe ANI Pharmaceuticals a future royalty of 5% on commercial sales of cretostimogene and there are no further payments due to ANI Pharmaceuticals for damages. Cretostimogene is CG Oncology’s investigational, intravesically delivered oncolytic immunotherapy in development for bladder cancer.
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with Viatris (NASDAQ:VTRS).
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 8.6%. This drop was discouraging since the S&P 500 held steady.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) exceeded Wall Street’s revenue expectations in Q1 CY2025, as sales rose 43.4% year on year to $197.1 million. Its non-GAAP EPS of $1.70 per share was 23% above analysts’ consensus estimates.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
ANI Pharmaceuticals Q1 revenue rose 43.4% to $197.12 million, EPS beat consensus, and 2025 guidance was raised on strong Cortrophin Gel and generics growth.
